SLC5A2 and heart failure: Reporting of cardiovascular safety was also absent in the included studies, and SGLT2 inhibitors were recently proven to reduce the risk of heart failure in patients with type 2 diabetes by the EMPA-REG OUTCOME study and CANAS study (23, 24).